Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359263 | 0.91 | PTGS2 (0.42) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL17359247 | 0.90 | PTGS2 (0.43) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL172359 | 0.88 | PDE3B (0.47) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL172423 | 0.87 | ACHE (0.48) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL17359248 | 0.86 | PDE3B (0.38) | RPS6KA3PTGS2PDE3BPDE3A | |
| SCHEMBL2741547 | 0.86 | PDE3B (0.42) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL2741562 | 0.86 | PDE3B (0.42) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL17359277 | 0.84 | CYP2A6 (0.42) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL17570168 | 0.84 | ACHE (0.46) | RPS6KA3PTGS2PTGS1PDE3BPDE3A | |
| SCHEMBL17570165 | 0.84 | AKR1C3 (0.45) | RPS6KA3PTGS2PTGS1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527870-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX3, OCIAD1, PIEZO1 | RPS6KA3 1591/4885PTGS2 4273/4885PTGS1 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.